GlassScriptPhysician profile
Hanna Kim
NPI 1487602017
$8,090.77
in general payments reported to CMS, 2019-2025
28 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $81.58 · 2021: $554 · 2022: $1,963 · 2023: $1,384 · 2024: $1,602 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,898 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,898.49 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,365.22 | 2021-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $1,363.79 | 2019-2025 | |
| Incyte Corporation | $1,252.73 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,104.20 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $639.53 | 2020-2025 | |
| Lilly USA, LLC | $505.00 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $312.60 | 2021-2023 | Seysara |
| Galderma Laboratories, L.P. | $216.59 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $174.30 | 2019-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $138.36 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $111.01 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $108.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $93.03 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $81.60 | 2023-2025 | Zoryve |
| Biofrontera INC. | $68.76 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $68.36 | 2019-2025 | Adbry |
| Verrica Pharmaceuticals INC. | $67.76 | 2023-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.52 | 2024-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.84 | 2023 | Jublia |
| Amgen INC. | $61.91 | 2022-2025 | Otezla |
| Strata Skin Sciences, INC. | $46.74 | 2022-2024 | Xtrac |
| Apyx Medical Corporation | $37.67 | 2019 | |
| Prugen, INC. Pharmaceuticals | $28.97 | 2019 | |
| Mayne Pharma Commercial LLC | $26.23 | 2019-2025 | |
| Organogenesis INC. | $24.61 | 2024 | Cygnus Dual |
| Krystal Biotech INC | $24.07 | 2024 | Vyjuvek |
| Genentech USA, INC. | $23.20 | 2020 | |
| Botanix Sb INC | $17.82 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanna Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.